We’re thrilled to announce the in vivo proof-of-concept for our small molecule-controlled gene therapy platform!

Our proprietary designer GPCR has demonstrated dose-dependent efficacy and safety, paving the way for precise neuromodulation in treatment-resistant neurological disorders like focal epilepsy

By merging the tunability of pharmacotherapy with the precision of gene therapy, we’re pioneering a new class of CNS therapeutics. Looking to learn more or collaborate? Let's shape the future of neuromodulation together!